| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
- Riva, M., et al.
(författare)
-
High-Priority Prototype Testing in Support of System-Level Design Development of the ITER Radial Neutron Camera
- 2018
-
Ingår i: IEEE Transactions on Plasma Science. - : IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC. - 0093-3813 .- 1939-9375. ; 46:5, s. 1291-1297
-
Tidskriftsartikel (refereegranskat)abstract
- This paper describes the high-priority testing activities supporting the ITER radial neutron camera (RNC) design, performed by a consortium of European institutes within a framework contract placed by fusion for energy, the ITER European Domestic Agency. The main role of the RNC is to measure the uncollided 14- and 2.5-MeV neutrons from deuterium-tritium and deuterium-deuterium fusion reactions through an array of flux monitors/spectrometers located in collimated lines of sight viewing the plasma through the ITER equatorial port plug #1. The line-integrated neutron fluxes will be used to evaluate, through reconstruction techniques, the radial profile of the neutrons emitted per unit time and volume (neutron emissivity) and, therefore, the neutron yield and the alpha particles' birth profile. The activity of high-priority testing is dedicated to the preparation and the design of experimental test environment, the conduction of appropriate tests and reporting of test results for the high-priority prototypes, clarifying or verifying the expected key function and system behavior, and enhancing learning on specific issues (potential showstoppers).
|
|
